Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Attends Ninth Indonesian Society of Interventional Cardiology Annual Meeting


Djakarta, Indonesia – From October 13 to October 15, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the Ninth Indonesian Society of Interventional Cardiology Annual Meeting ("ISICAM-InaLive") held in Djakarta, Indonesia, to display its Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), Firebird2® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird2®") and other cardiovascular products. Focused on "Integrative Strategies in Cardiovascular Intervention", the annual meeting attracted over 700 professionals from Indonesia, Japan, Singapore and etc to attend.
During the meeting, several renowned cardiologists, such as Professor A. Fauzi Yahya, Chairman of ISICAM-InaLive, Professor Sunarya Soerianata, President of Indonesian Society of Interventional Cardiology, and Professor Teguh Santoso of Medistra Hospital, visited MicroPort® booth and had in-depth discussion with MicroPort® representatives regarding the design rationale and clinical data of Firehawk® and Firebird2®. They spoke highly of Firehawk®‘s clinical performance, in particular, its excellent crossability and compliance.
Ischemic cardiovascular diseases are the leading killer of Indonesians, causing 37% of death annually. In recent years, there is growing demand for cardiovascular interventional products in the Indonesia market with the rapid development of the local healthcare market. Currently, several cardiovascular interventional products in-house developed by MicroPort®, including Firehawk®, Firebird2®, and FOXTROT PRO PTCA Balloon Dilatation Catheter, have entered the Indonesia market, and have won high recognition from patients and physicians with their outstanding performance. In January 2014, Indonesia launched its universal healthcare program to provide health insurance to all Indonesian by January 2019. MicroPort® would take this opportunity to further cultivate the market in the "Belt and Road" initiative to provide high-quality and cost-effective medical solutions to local patients with cardiovascular diseases.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Endovascular Hosts Product Launch of Castor®
[Next]:MicroPort® EP's Contact Force Sensing RF Ablation Catheter Gains CFDA Green-Path